Abstract
Triamcinolone acetonide (TAA) aerosol nasal inhaler is an effective and well-tolerated treatment for symptoms of perennial allergic rhinitis (PAR). This multicenter, randomized, double-blind, placebo-controlled study evaluated the efficacy and safety of once-daily administration of TAA aerosol nasal inhaler (220 μg) in a pediatric population 6-11 years of age, with a documented history of PAR, a positive skin prick test for perennial allergens, and a minimum qualifying total rhinitis symptom score (≥24 points of a possible 48). One hundred thirty-seven patients received either TAA aerosol nasal inhaler (220 μg/day) or placebo once daily for 4 weeks. Patients evaluated the severity of PAR symptoms (nasal stuffiness, discharge, sneezing, itching) daily according to a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe). Patients' and physicians' global evaluations of overall treatment effectiveness were assessed after the 4-week treatment period. Patients treated with TAA aerosol nasal inhaler had significantly (p < 0.05) greater reductions in all nasal symptom scores overall and in nasal stuffiness and nasal index at the end of weeks 1, 2, 3, and 4 compared with the placebo group. Both patients' and physicians' global evaluations of efficacy favored TAA aerosol nasal inhaler compared with placebo. Adverse events were mild and comparable between the two groups. This study demonstrated that once-daily administration of TAA aerosol nasal inhaler (220 μg) was well tolerated and effective in reducing the symptoms of PAR in pediatrie patients.
Get full access to this article
View all access options for this article.